9 results about "Active transport" patented technology

The invention relates to the technical field of antitumor drugs, in particular to a Ru (II) complex and a preparation method and application thereof, and the Ru (II) complex has a structure as shown in a formula I. The Ru (II) complex synthesized by the method disclosed by the invention not only has relatively high cytotoxicity, but also has good photodynamic antitumor activity. After the complex is illuminated, the efficiency of the complex entering cells in an active transportation mode can be accelerated, mitochondria and endoplasmic reticulum are targeted at the same time, mitochondrial membrane potential decline and endoplasmic reticulum stress are caused to form a dual organelle damage effect, immunogenic cell death is caused, the tumor microenvironment is adjusted, and the tumor cell immunogenicity is improved. The enrichment of dendritic cells (DCs) in tumor cells is realized, the chemotactic activity of effector T cells is improved, the proportion of CD4 < + > and Foxp3 < + > cell populations is reduced, and finally the anti-tumor immune response is activated. Meanwhile, the complex provided by the invention can also induce the cell to generate pan apoptosis, retard the cell cycle in the G2 / M period and enhance the effect of the complex in inhibiting tumor proliferation.

The present invention discloses a method for evaluating and predicting placental transport efficiency, comprising the following steps: S1: respectively measuring and analyzing PFASs in different test samples; S2: TTE estimation: calculating TTE0 and TTE(tem) according to the following formula: TTE0=C PFAS‑脐带血清 / C PFAS‑母体血清 、C PFAS‑母体血 ×V 母体血 ×TTE m =C PFAS ‑ 脐带血 ×V 脐带血 、C PFAS‑血清 / R=C PFAS‑全血 S3: Statistical Analysis. The present invention successfully identified differences in TTE between SGA infants and matched healthy controls using an improved TEM model that considers total PFAS exposure. The improved TEM model exhibited advantages in active transport and facilitated diffusion.

The invention relates to the technical field of medicines, in particular to application of ginsenoside in preparation of medicines for improving kidney inflammation and enhancing uric acid excretion. It is found for the first time that ginsenoside Rg2 can reduce systematic and kidney inflammatory reactions by reducing expression levels of inflammatory factors LPS, TNF-alpha and IL-1beta; by down-regulating the expression level of fibrosis marker molecules alpha-SMA and Smad3, the effect of improving HUA-related kidney inflammation and fibrosis is achieved; by up-regulating the expression levels of uric acid transporters OAT1, OAT3 and ABCG2, the active transport and excretion ability of the kidney to uric acid is enhanced. The discovery can generate great influence on research and treatment of relieving hyperuricemia, and has clinical practical value.

The application discloses a kind of pectinatocarpus selenium protein peptide and albumin peptide formula and preparation method, the core active ingredient of the formula is the selenium protein peptide of pectinatocarpus source and egg white albumin peptide, wherein the number average molecular weight of selenium protein peptide is 461Da, total selenium is 412.67mg / kg and selenocysteine and pectinatocarpus plant selenium peptide ratio is more than 90%, and the biological potency of albumin peptide is 94, and the molecular weight is 200-800Da;The application promotes active transport in intestinal tract by albumin peptide as carrier, and is prepared by combining dry granulation and tabletting process, the selenium absorption rate of the application is greatly improved, realizes the synergistic effect of hypoglycemic, hypolipidemic and antioxidant, and provides a new scheme for selenium supplement functional food.

The present disclosure provides a nanocomposite and a preparation method and use thereof. In the present disclosure, the nanocomposite is wrapped with Prussian blue nanoparticles (PB) using a platelet membrane (PM) as a shell; and a surface of the PM is modified with an aptamer of cancer cells and horseradish peroxidase (HRP). An ability of platelets (PLTs) to specifically target cancer cells and inflammatory sites can effectively enhance the accumulation of nanoparticles at tumor sites, and help PB better achieve a desirable photothermal therapy (PTT) under near-infrared light irradiation. In addition, hydrogen peroxide is highly expressed in the tumor microenvironment; the HRP modified on a surface of the nanocomposite can decompose the hydrogen peroxide to generate oxygen bubbles, which drive active transport of the nanocomposite, thereby enhancing the accumulation in cancer cells. Modification with the aptamer of cancer cells on a platelet membrane surface enhances cancer cell targeting.

The invention relates to the technical field of biomedicine, in particular to an organoid virus transfection method based on filter membrane mediation, which comprises the following steps: providing an organoid suspension which is mildly digested and retains part of matrigel; centrifuging in a container containing a microporous filter membrane, so that the organoid is flatly laid on the surface of the filter membrane to form a thin film; transferring the filter membrane bearing the organoid to an electric transfer device to be in contact with a virus vector, and applying an electric field to drive viruses to penetrate through the filter membrane and residual matrigel to enter cells; geometric shielding is eliminated through centrifugal tiling, and diffusion obstruction of matrigel is overcome through active transportation of electric field force; according to the method, the transfection efficiency and uniformity of the virus vector are remarkably improved on the premise of maintaining the integrity of the three-dimensional structure and high cell activity of the organoid, and the problem that the efficiency and the structure cannot be obtained at the same time in the prior art is solved.

The application discloses a kind of liquid management and spontaneous power generation dual bionic wound dressing and preparation method and application.The dual bionic wound dressing includes first electrode layer, barrier layer, hygroscopic power generation layer, diffusion antibacterial layer, evaporation power generation layer and second electrode layer stacked in order from bottom to top;The application adopts high biocompatibility electrostatic spinning fiber membrane, realizes the triple function of wound antibacterial, seepage efficient management and stable power generation by combining the liquid transport mechanism of plant transpiration with the ion active transport principle of electric ray power generation cell through bionic design, regulates wound microenvironment, effectively avoids excessive inflammation caused by seepage accumulation, significantly promotes fibroblast migration, angiogenesis and skin appendage regeneration, accelerates wound healing, and is beneficial to restore skin function, provides a new treatment for burn wound repair.

An improved oral therapy delivery system with enhanced permeability, and an innovative method of manufacture. The therapy delivery system is comprised of a ternary, oil in water emulsion containing three (3) phases; a first aqueous phase that is hydrophilic, a second oil phase that is lipophilic, and a third activation or permeability enhancement phase. This three-phase construction allows delivery of both water soluble and oil soluble compounds, with increased activation of either or both. The third activation phase, in some embodiments, is comprised of 4 cellularly vital compounds capable of triggering active transport of material adjacent to cellular surfaces. These 4 compounds are vital for cellular functioning as incentives to trigger active transport of medicinal material.

The invention belongs to the technical field of biological medicines, and particularly relates to an efficient brain-targeted oxytocin nasal spray for resisting oxycodone addiction. The nasal spray comprises a polyelectrolyte complex formed by amino acid grafted chitosan and anionic polysaccharide, wherein oxytocin is loaded in the polyelectrolyte complex. The amino acid is selected from tryptophan, leucine or tyrosine. The preparation is administrated through a nasal cavity, the brain targeting property and bioavailability of oxytocin are remarkably improved by utilizing an LAT-1 transporter mediated active transport mechanism, and the preparation is used for preventing or treating addiction of opioid drugs such as oxycodone and the like. Experiments show that the preparation can significantly enhance distribution of oxytocin in the brain, inhibit formation and relapse of addiction and promote drug withdrawal, and has a good application prospect.